Zacks Small Cap Brokers Reduce Earnings Estimates for QNRX

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) – Research analysts at Zacks Small Cap reduced their FY2024 earnings per share estimates for Quoin Pharmaceuticals in a report released on Tuesday, November 12th. Zacks Small Cap analyst M. Marin now expects that the company will post earnings of ($2.05) per share for the year, down from their previous forecast of ($2.02). The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.02) per share. Zacks Small Cap also issued estimates for Quoin Pharmaceuticals’ FY2025 earnings at ($2.00) EPS.

Quoin Pharmaceuticals Price Performance

Shares of NASDAQ QNRX opened at $0.62 on Thursday. Quoin Pharmaceuticals has a 12-month low of $0.48 and a 12-month high of $6.18. The firm’s 50-day simple moving average is $0.65 and its 200 day simple moving average is $0.65. The company has a market cap of $3.12 million, a price-to-earnings ratio of -0.15 and a beta of 1.85.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 30,749 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.77% of Quoin Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 8.63% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.